April 2024 in “Journal of asthma and allergy” Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.
April 2024 in “Dermatology and therapy” In Denmark from 1995 to 2016, hospital-treated alopecia areata cases increased, mostly affecting women and those over 50.
February 2024 in “International neuropsychiatric disease journal” Alopecia areata severely impacts quality of life, mental health, and work productivity.
October 2023 in “Frontiers in medicine” Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.
June 2023 in “Dermatology and therapy” Doctors in the Middle East need better treatments and more knowledge about new therapies for hair loss condition Alopecia Areata.
January 2019 in “ARC journal of pharmaceutical sciences” Acne can be managed with various treatments and requires psychological support due to its emotional impact.
March 2018 in “Suez Canal University Medical Journal” New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.
June 2016 in “Annals of the rheumatic diseases” Methotrexate is effective for treating rheumatoid arthritis but requires regular monitoring.
May 2014 in “Journal of The American Academy of Dermatology” The document lists various dermatology topics, treatments, and diagnostic methods.
December 2023 in “Journal of dermatology” Adults and adolescents with severe alopecia areata are willing to take significant health risks for a better chance of hair regrowth.
4 citations,
March 2023 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.
October 2024 in “European Journal of Medicinal Chemistry” New small molecule drugs could help treat hair loss.
355 citations,
January 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
4 citations,
January 2023 in “Skin health and disease” Blocking Janus kinase 1 helps stop inflammation and regrow hair, making it a good treatment for hair loss from alopecia areata.
2 citations,
June 2023 in “Indian journal of dermatology, venereology, and leprology” Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.
2 citations,
October 2022 in “Current Allergy and Asthma Reports” Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.
88 citations,
August 2019 in “Frontiers in immunology” Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.
55 citations,
October 2019 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.
21 citations,
May 2017 in “Paediatric drugs” Individualized treatment plans are crucial for children with alopecia areata, with promising options like JAK inhibitors showing significant hair regrowth.
18 citations,
June 2019 in “Clinical research in dermatology” Acne can't be cured but can be managed with treatments like benzoyl peroxide and diet changes; it's costly and can lead to scarring and mental health issues.
17 citations,
January 2019 in “Journal of cutaneous medicine and surgery” JAK inhibitors show promise for treating hair loss in alopecia areata but need more clinical trials to confirm safety and effectiveness.
16 citations,
June 2018 in “JAAD case reports” A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
15 citations,
January 2022 in “Journal of Infection” COVID-19 vaccines are safe and highly effective for children, with inactivated vaccines being slightly better.
2 citations,
November 2023 in “Acta dermato-venereologica” Tofacitinib is effective and safe for treating alopecia areata with a good drug survival rate.
2 citations,
November 2021 in “ACG Case Reports Journal” Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.
1 citations,
December 2023 in “Molecules/Molecules online/Molecules annual” JAK inhibitors show promise for treating various skin diseases.
1 citations,
October 2023 in “Advanced Drug Delivery Reviews” Microneedles are promising for long-acting drug delivery and can improve patient compliance, but more data is needed to confirm their effectiveness.
1 citations,
September 2023 in “Stem cell research & therapy” Mesenchymal stem cells could help treat aging-related diseases better than current methods.
1 citations,
May 2021 in “BMC Proceedings” The document concludes that more research is needed to reduce frequent hospital visits, addiction medicine education improves with specific training, early breast cancer surgery findings are emerging, nipple smears are not very accurate, surgery for older melanoma patients doesn't extend life, a genetic condition in infants can often be treated with one drug, doctors are inconsistent with blood clot medication, a certain gene may protect against cell damage, muscle gene overexpression affects many other genes, and some mitochondrial genes are less active in mice with tumors.
1 citations,
May 2017 in “InTech eBooks” New treatments focusing on immune pathways show promise for stubborn hair loss.